Name | Maraviroc |
Synonyms | Maraviroc 4,4-difluoro-N-[(1S)-3-{3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl]cyclohexanecarboxamide 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide 4,4-difluoro-N-[(1S)-3-{(1R,5S)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl]cyclohexanecarboxamide |
CAS | 376348-65-1 |
EINECS | 609-456-0 |
InChI | InChI=1/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1 |
Molecular Formula | C29H41F2N5O |
Molar Mass | 513.67 |
Density | 1.29g/cm3 |
Melting Point | 79-81°C |
Storage Condition | -20℃ |
Refractive Index | 1.627 |
MDL | MFCD13188530 |
Physical and Chemical Properties | Density 1.29±0.1g/cm3(Predicted) Storage Conditions room temp Solubility DMSO: >30 mg/mL Acidity Coefficient (pKa) 7.3(at 25 ℃) Form white powder |
Use | In Malawi, if the new anti-HIV drug approved by the US Food and Drug Administration on August 6, 2007, the drug was developed by Pfizer, CCR5 receptor is a necessary pathway for HIV infection, so it can be used as a broad-spectrum anti-HIV drugs. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 48/22 - Harmful danger of serious damage to health by prolonged exposure if swallowed. |
Safety Description | S22 - Do not breathe dust. S36 - Wear suitable protective clothing. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.947 ml | 9.734 ml | 19.468 ml |
5 mM | 0.389 ml | 1.947 ml | 3.894 ml |
10 mM | 0.195 ml | 0.973 ml | 1.947 ml |
5 mM | 0.039 ml | 0.195 ml | 0.389 ml |